CPTC-PTPN2-1 (CAB080378)

Uniprot ID: P17706

Protein name: PTN2_HUMAN

Full name: Tyrosine-protein phosphatase non-receptor type 2

Tissue specificity: Ubiquitously expressed. Isoform 2 is probably the major isoform. Isoform 1 is expressed in T-cells and in placenta.

Function: Non-receptor type tyrosine-specific phosphatase that dephosphorylates receptor protein tyrosine kinases including INSR, EGFR, CSF1R, PDGFR. Also dephosphorylates non-receptor protein tyrosine kinases like JAK1, JAK2, JAK3, Src family kinases, STAT1, STAT3 and STAT6 either in the nucleus or the cytoplasm. Negatively regulates numerous signaling pathways and biological processes like hematopoiesis, inflammatory response, cell proliferation and differentiation, and glucose homeostasis. Plays a multifaceted and important role in the development of the immune system. Functions in T-cell receptor signaling through dephosphorylation of FYN and LCK to control T-cells differentiation and activation. Dephosphorylates CSF1R, negatively regulating its downstream signaling and macrophage differentiation. Negatively regulates cytokine (IL2/interleukin-2 and interferon)-mediated signaling through dephosphorylation of the cytokine receptors. Also regulates the Ll6/interleukin-6 and IL4/interleukin-4 cytokine signaling through dephosphorylates CST11, that propagate signaling downstream of the cytokine receptors. Also regulates the Ll6/interleukin-6 and IL4/interleukin-4 cytokine signaling through dephosphorylates EGFR and negatively regulates EGF signaling. Dephosphorylates PDGFRB and negatively regulates glatelet-derived growth factor receptor-beta signaling pathway and therefore cell proliferation. Negatively regulates tumor necrosis factor-mediated signaling downstream via MAPK through SRC dephosphorylation. May also regulate the hepatocyte growth factor receptor signaling pathway through the dephosphorylation of TNSR and control gluconeogenesis and liver glucose production through negativel regulates the insulin receptor signaling pathway through the dephosphorylation of INSR and control gluconeogenesis and liver glucose production through negativel regulates the insulin receptor signaling pathways. May also bind DNA. **Subcellular location**:

Isoform 1:

Endoplasmic reticulum (experimental evidence)

Endoplasmic reticulum-Golgi intermediate compartment (experimental evidence)

NOTE: Targeted to the endoplasmic reticulum by its C-terminal hydrophobic region.

Isoform 2:

Nucleus


Cytoplasm

Cell membrane

NOTE: Predominantly localizes to chromatin (By similarity). Able to shuttle between the nucleus and the cytoplasm and to dephosphorylate plasma membrane receptors (PubMed:9488479). Recruited by activated ITGA1 at the plasma membrane. **Protein existence**: Experimental evidence at protein level


Comment: No staining was observed in any cell line/Charlotte

Immunohistochemistry



IHC protocol:	HIER pH6, Dilution 1:150	
IHC test staining:	Plasma positivity in kidney.	
Literature conformance:	Not consistent with gene/protein characterization data	
Literature significance:		
RNA similarity:	Very low consistency between antibody staining and RNA expression data	
RNA tissue specificity:	Tissue enhanced (lymphoid tissue)	
RNA tissue distribution:	Detected in all	
IHC Sibling similarity:	Other antibody shows dissimilar IHC staining pattern	

Immunofluorescence



IF Overlay:	antibody (green), anti-tubulin (red) and DAPI (blue)
IF main location:	
IF additional location:	
IF approved for publication on HPA:	No
IF in THP-1:	Negative
IF in U2OS:	Negative

Western blot

	WB Size markers (kDa):	250, 130, 100, 70, 55, 35, 25, 15, 10
1	WB Lanes:	Marker (1), RT-4 (2), U-251MG (3), Plasma (4), Liver (5), Tonsil (6)
	WB Target weight (kDa):	8, 13, 17, 18, 36, 36, 41, 45, 45, 48, 48
and a second second	WB Validation:	Supported (Single band corresponding to the predicted size in kDa (+/-20%).)